Showing results (1-10 of 5,979) with videos related to
Sort By:
Pageof 598
Journal of Immunology Research|March 22, 2016
Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and ProspectsYelei Guo, Yao Wang, Weidong HanProtein & Cell|March 15, 2017
Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatmentYelei Guo, Kaichao Feng, Yao Wang, et al.Chinese Journal of Cancer|May 13, 2015
Cytokine-induced killer (CIK) cells: from basic research to clinical translationYelei Guo, Weidong HanProtein & Cell|May 4, 2017
Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatmentZhenguang Wang, Yelei Guo, Weidong HanScience China. Life Sciences|March 13, 2016
Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancerKaichao Feng, Yelei Guo, Hanren Dai, et al.Molecular Cancer Therapeutics|January 18, 2026
MCT1 inhibition remodels the tumor immune microenvironment for enhanced cancer immunotherapyYipeng Zhang, Chun Liu, Fuxin Han, et al.Cellular & Molecular Immunology|October 1, 2020
Clinical development of CAR T cell therapy in China: 2020 updateJianshu Wei, Yelei Guo, Yao Wang, et al.Journal for Immunotherapy of Cancer|August 9, 2019
PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activityJianshu Wei, Can Luo, Yao Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2017
Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract CancersYelei Guo, Kaichao Feng, Yang Liu, et al.Protein & Cell|July 16, 2017
Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancersKaichao Feng, Yang Liu, Yelei Guo, et al.Pageof 598